Toggle light / dark theme

Bioelectronics research and development of implants made of electrically conductive materials for disease treatment is advancing rapidly. However, bioelectronic treatment is not without complications. Researchers at Lund University in Sweden have taken another step forward by developing a refined method to create detailed and tissue-friendly bioelectronics.

In a study published in Advanced Science, the researchers describe how they can use light to create electrically directly in the body, showing promising results in animal trials.

Bioelectronics is successfully used for treating heart arrhythmia, epilepsy, and like Parkinson’s, to name a few. However, it’s well known that today’s bioelectrodes and implantation methods require the tissue to adapt to the electrodes, rather than the other way around. This can lead to complications.

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

This trial marks a new frontier in —the process of treating or curing medical conditions by changing a person’s genes.

What makes it special is the fact the therapy targets RNA, instead of DNA. So, what does that mean, and why should we be excited?

Heeding those sentiments, the Australian Army is strategically investing in technological innovation to find better solutions to the complex logistics challenges they face in managing the efficient and safe deployment of personnel and equipment on the battlefield. For a difficult class of problems in an area called “optimization”, quantum computing is on the roadmap for exploration.

With the help of our quantum infrastructure software, they’ve now been able to test and validate a quantum computing solution on real hardware that promises to outperform their existing methods.